Maurizio Fraziano     bandiera-inglese

foto maurizio (2)

Curriculum Vitae

(1992) Degree in Biological Sciences, at the University of Rome “La Sapienza”; (1996) PhD in “Cellular Differentiation and Morphogenesis” at the University of L’Aquila; (1995) PhD student at the Division of Oncology of “St. George’s Hospital Medical School”, London (Scientific Director: Prof. A.G. Dalgleish); (1996-2001) UNESCO fellowship at the Department of Biology, University of Rome “Tor Vergata”; (2001 to present) Researcher atthe Department of Biology, University of Rome “Tor Vergata”. He is author of 71 scientific papers on indexed journals and founder of a Start-up called BioLT – Bioactive Liposome Therapeutics Srls .

 

Teaching activity

(2001 to now): Immunotechnology (2 ECTS), Immunology (3 ECTS), Molecular basis of cell response to infections (3 ECTS), Immunology and Pathology (6 ECTS), Infection and Immunity (6 ECTS), Bacteriology of human pathogens (3 ECTS).

 

Research topics

  • Host - pathogen interaction: analysis of the role played by second lipid messengers in the activation of phagocytosis.
  • Identification of novel immunotherapeutic anti-infective strategies: generation of asymmetric apoptotic body-like liposomes and their analysis in terms of capability to modulate antimicrobial and inflammatory response in vitro, in vivo (in murine models) and ex vivo (in cells from cystic fibrosis patients) experimental settings.
  • Analysis of endogenous adjuvants for the generation of novel anti-tuberculosis vaccine formulations.

 

Fundings (last 5 years)

1. Fondazione Italiana Fibrosi Cistica 2022 - (2 years project) – Title: Fighting Mycobacterium abscessus by a novel combination therapy. Funding: 130.000 euro

2. Piano Nazionale Ricerca Militare 2019, Italian Ministry of Defense – 2 years project  - Titolo: mRNA encapsulated in asymmetric liposomes as a vaccine platform in biodefence (REAL-BIODEFENCE). Funding: 165.000 euro

3. Fondazione Italiana Fibrosi Cistica 2019 - (2 years project) – Title: “Preclinical study of a combined host- and pathogen- directed approach based on bioactive liposomes and bacteriophages against Mycobacterium abscessus infection”. Funding: 120000 euro.

4. Fondazione Italiana Sclerosi Multipla (2018) – (3 years project) – Title: Liposome “Janus-faced liposomes as therapeutic tools to drive Tsuppressor phenotype in multiple sclerosis. Funding: 148000 euro

5. Fondazione Italiana Fibrosi Cistica 2017 – (1 year project) – Title: “Preclinical study of a host-directed therapy based on Metformin and bioactive liposomes for the control of multidrug resistant P. aeruginosa infection”. Funding: 40000 euro.

 

Patents

  • Fraziano M., Garg S.K., Volpe E., Martino A., De Vito P., Baldini M., Galati D., Auricchio G., Ciaramella A., Colizzi V. Immunoregulatory compounds. Brevetto No. PCT/IT02/00740.
  • Fraziano M., De Spirito M., Greco E., Quintiliani G. Liposomiasimmetrici e loro usi in campo medico.Brevetto No. RM2007A000394 del 16 luglio 2007.

 

Publications (last 5 years)

1. Tredicine M, Ria F, Poerio N, Lucchini M, Bianco A, De Santis F, Valentini M, De Arcangelis V, Rende M, Stabile AM, Pistilli A, Camponeschi C, Nociti V, Mirabella M*, Fraziano M*, Di Sante G.* Liposome-based nanoparticles impact on regulatory and effector phenotypes of Macrophages and T cells in Multiple Sclerosis patients. Biomaterials (in press). *Equally contributed as senior authors.

2. Cafora M, Poerio N, Forti F, Loberto N, Pin D, Bassi R, Aureli M, Briani F, Pistocchi A, Fraziano M. Evaluation of phages and liposomes as combination therapy to counteract Pseudomonas aeruginosa infection in wild-type and CFTR-null models. Front Microbiol. 2022 Sep 15;13:979610.

3. Di Giacomo C, Pucillo L, Sevilla C, Fucci G, Massoud R, Bernardini S, Fraziano M, Gentile G. 25-Hydroxyvitamin D Plasma Levels in Natural Populations of Pigmented and Partially Pigmented Land Iguanas from Galápagos (Conolophusspp.). Biomed Res Int. 2022 Jul 14;2022:7741397.

4. De Santis F., Borrajo Lopez A., Virtuoso S., Poerio N., Saccomandi P., Olimpieri T., Duca L., Henrici De Angelis L., Aquilano K., D’Andrea M.M., Aquaro S., Borsetti A., Ceccherini-Silberstein F., Fraziano M. Phosphatidylcholine liposomes down-modulate CD4 expression reducing HIV entry in human type-1 macrophages. (Front. Immunol. 2022;13: 830788)

5. Henrici De Angelis L., Ponsecchi G., Fraziano M., D’Andrea M.M. Application of Bacteriophages for human health: an old Approach against contemporary “bad bugs”. Microorganisms. 2022;10: 485)

6. Poerio N., Olimpieri T., Henrici De Angelis L., De Santis F., Thaller M.C.., D’Andrea M.M., Fraziano M. Fighting MDR- Klebsiella pneumoniae infections by a combined host- and pathogen- directed therapeutic approach. (Front. Immunol. 2022; 13: 835417).

7. Poerio N., Riva C., Olimpieri T., Rossi M, Lorè NI, De Santis F, Henrici De Angelis L, Ciciriello F, D’Andrea MM, Lucidi V, Cirillo DM, Fraziano M. Combined host- and pathogen-directed therapy for the control of Mycobacterium abscessus infection. (Microbiol Spectr 2022 Feb 23;10(1):e0254621).

8. Poerio N., Caccamo N., La Manna M.P., Olimpieri T., Henrici De Angelis L., D’Andrea M.M., Dieli F., Fraziano M. Phosphatidylserine liposomes reduce inflammatory response, mycobacterial viability and HIV replication in coinfected human macrophages. (J Infect Dis. 2021 Dec 15:jiab602. doi: 10.1093/infdis/jiab602).

9. Rinaldi F., Hanieh P.N., Sennato S., De Santis F., Forte J., Fraziano M., Casciardi S., Marianecci C., Bordi F., Carafa M. Rifampicin-Liposomes for Mycobacterium abscessus Infection Treatment: Intracellular Uptake and Antibacterial Activity Evaluation. (Pharmaceutics. 2021; 13:1070).

10. Grassi G., Vanini V., De Santis F., Romagnoli A., Aiello A., Casetti R., Cimini E., Bordoni V., Notari S., Cuzzi G., Mosti S., Gualano G., Palmieri F., Fraziano M., Goletti D., Agrati C., Sacchi A. PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. (Front Immunol. 2021; 12:594376).

11. Henrici De Angelis L., Poerio N., Di Pilato V., De Santis F., Antonelli A., Thaller M.C., Fraziano M., Rossolini G.M., D’Andrea M. M. Phage Resistance Is Associated with Decreased Virulence in KPC-Producing Klebsiella pneumoniae of the Clonal Group 258 Clade II Lineage (Microorganisms. 2021; 9: 762)

12. Nisini R., Oggioni M.R., Rossolini G.M., Fraziano M. Exploiting Novel Combined Host- and Pathogen- Directed Therapies for Combating Bacterial Multidrug Resistance (Front. Immunol., 2020; 11: 616486)

13. Cirotti C., Rizza, S. Giglio P., Poerio N., Allega M., Claps G., Pecorari C., Lee JH, Benassi B., Barilà D., Robert C., Stamler J., Cecconi F., Fraziano M., Paull T. and Filomeni G. Redox activation of ATM enhances GSNOR translation to sustain mitophagy and tolerance to oxidative stress (EMBO Rep, 2020; 22: e50500)

14. Poerio N., De Santis F., Rossi A., Ranucci S., De Fino I., Henriquez A., D’Andrea M.M., Ciciriello F.,  Lucidi V.,  Nisini R., Bragonzi A., Fraziano M. Liposomes loaded with phosphatidylinositol 5- phosphate improve the antimicrobial response to Pseudomonas aeruginosa in impaired macrophages from Cystic Fibrosis patients and limit airway inflammatory response (Front. Immunol. 2020; 11: 532225)

15. Marmo P., Thaller M.C., Di Lallo G., Henrici De Angelis L., Poerio N., De Santis F., Fraziano M., Migliore L., D’Andrea M.M. Characterization of vB_StuS_MMDA13, a Newly Discovered Bacteriophage Infecting the Agar-Degrading Species Sphingomonas turrisvirgatae. (Viruses. 2020;12: E894).

16. D’Andrea M.M., Fraziano M., Thaller M.C., Rossolini G.M. The Urgent Need for Novel Antimicrobial Agents and Strategies to Fight Antibiotic Resistance. Antibiotics (Basel). 2019 Dec 6;8(4). pii: E254.

17. Aquilano K., Ceci V., Gismondi A., De Stefano S., Iacovelli F., Faraonio R., Di Marco G., Poerio N., Minutolo A., Minopoli G., Marcone A., Fraziano M., Tortolici F., Sennato S., Casciardi S., Potestà M., Bernardini R., Mattei M., Falconi M., Montesano C., Rufini S., Canini A., Lettieri-Barbato D. Adipocyte metabolism is improved by TNF receptor-targeting small RNAs identified from dried nuts. (Commun Biol. 2019; 2: 317)

18. Diogo G.R., Hart P., Copland A., Kim M.Y., Tran A.C., Poerio N., Singh M., Paul M.J., Fraziano M., Reljic R. Immunization With Mycobacterium tuberculosis Antigens Encapsulated in Phosphatidylserine Liposomes Improves Protection Afforded by BCG. (Front Immunol. 2019 Jun 12;10:1349)

19. Chiriaco M., Di Matteo G., Conti F., Petricone D., De Luca M., Di Cesare S., Cifaldi C., De Vito R., Zoccolillo M., Serafinelli J., Poerio N., Fraziano M., Brigida I., Cardinale F., Rossi P., Aiuti A., Cancrini C., Finocchi A. First Case of Patient With Two Homozygous Mutations in MYD88 and CARD9 Genes Presenting With Pyogenic Bacterial Infections, Elevated IgE, and Persistent EBV Viremia. (Front Immunol. 2019; 10: 130)

20. De Santis F., Poerio N., Gismondi A., Nanni V., Di Marco G., Nisini R., Thaller M.C.,  Canini A., Fraziano M. Hydroalcoholic extract from Origanum vulgare induces a combined anti-mycobacterial and anti-inflammatory response in innate immune cells. (PLoS One. 2019; 14: e0213150)

21. Volpe E., Cesari E., Mercatelli N., Cicconi R., De Bardi M., Capone A., Bonvissuto D., Fraziano M., Mattei M., Battistini L., Paronetto M.P., Sette C. The RNA binding protein Sam68 controls T helper 1 differentiation and anti-mycobacterial response through modulation of miR-29. (Cell Death Differ. 2019; 26: 1169-1180)

22. Ciacci N., D’Andrea M.M., Marmo P., Demattè E., Amisano F., Di Pilato V., Fraziano M., Lupetti P., Rossolini G.M., Thaller M.C. Characterization of vB_Kpn_F48, a Newly Discovered Lytic Bacteriophage for Klebsiella pneumoniae of Sequence Type 101. (Viruses. 2018; 10: E482)

23. Nisini R., Poerio N., Mariotti S., De Santis F., Fraziano M. The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases. (Front Immunol. 2018; 9:155)

24. Mariotti S., Pardini M., Teloni R., Gagliardi M.C., Fraziano M., Nisini R. A method  permissive to fixation and permeabilization for the multiparametric analysis of apoptotic and necrotic cell phenotype by flow cytometry. (Cytometry A. 2017; 91: 1115-1124)

25. Poerio N., Bugli F., Taus F., Santucci M.B., Rodolfo C., Cecconi F., Torelli R., Varone F., Inchingolo R., Majo F., Lucidi V., Mariotti S., Nisini R., Sanguinetti M., Fraziano M. Liposomes loaded with bioactive lipids enhance antibacterial innate immunity irrespective of drug resistance. (Sci Rep 2017; 7: 45120)

26. Chiriaco M., Brigida I., Ariganello P., Di Cesare S., Di Matteo G., Taus F., Cittaro D., Lazarevic D., Scarselli A., Santilli V., Attardi E., Stupka E., Giannelli S., Fraziano M., Finocchi A., Rossi P., Aiuti A., Palma P., Cancrini C. The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. (Clin Immunol. 2017; 178: 20-28).